Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eperisone + paracetamol
- Development stage
- Unknown
- Lead developer
- ADN Life Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Relaxone Plus is a fixed-dose combination tablet containing the muscle relaxant eperisone and the analgesic/antipyretic paracetamol (acetaminophen). Developed and marketed by ADN Life Sciences, it is approved for the treatment of pain and discomfort associated with acute muscle spasms and musculoskeletal conditions. Eperisone acts as a centrally acting muscle relaxant by blocking voltage-gated calcium and sodium channels, thereby reducing spinal reflexes and improving blood flow to skeletal muscles. Paracetamol provides complementary pain relief and fever reduction by inhibiting cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. Together, the combination effectively alleviates muscle stiffness, reduces pain, and improves mobility.
- Brand names
- Relaxone Plus
- Other names
- eperisone + acetaminopheneperisone + paracetamoleperisone hydrochloride + acetaminopheneperisone hydrochloride + paracetamol
02
Targets
P2RX7 (P2X purinoceptor 7)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on eperisone + paracetamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eperisone + paracetamol.